JP7868811B2 - イヌ細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対するイヌモノクローナル抗体 - Google Patents
イヌ細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対するイヌモノクローナル抗体Info
- Publication number
- JP7868811B2 JP7868811B2 JP2023565183A JP2023565183A JP7868811B2 JP 7868811 B2 JP7868811 B2 JP 7868811B2 JP 2023565183 A JP2023565183 A JP 2023565183A JP 2023565183 A JP2023565183 A JP 2023565183A JP 7868811 B2 JP7868811 B2 JP 7868811B2
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177692P | 2021-04-21 | 2021-04-21 | |
| US63/177,692 | 2021-04-21 | ||
| PCT/US2022/025614 WO2022226102A1 (en) | 2021-04-21 | 2022-04-20 | Canine monoclonal antibodies against canine cytotoxic t lymphocyte associated protein 4 (ctla-4) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024516621A JP2024516621A (ja) | 2024-04-16 |
| JP2024516621A5 JP2024516621A5 (cg-RX-API-DMAC7.html) | 2025-04-08 |
| JP7868811B2 true JP7868811B2 (ja) | 2026-06-02 |
Family
ID=83723402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565183A Active JP7868811B2 (ja) | 2021-04-21 | 2022-04-20 | イヌ細胞傷害性tリンパ球関連タンパク質4(ctla-4)に対するイヌモノクローナル抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US12110331B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4326324A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7868811B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3216131A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022226102A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4326324A4 (en) * | 2021-04-21 | 2026-03-25 | Univ Pennsylvania | Canine Monoclonal Antibodies Against Canine Cytotoxic T Lymphocyte-Associated Protein 4 (CTLA-4) |
| CN120265660A (zh) * | 2023-04-28 | 2025-07-04 | 宾夕法尼亚大学董事会 | 新型cd19靶向多肽和cd19定向免疫疗法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040181039A1 (en) | 2001-12-21 | 2004-09-16 | Krah Eugene Regis | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| WO2021009187A1 (en) | 2019-07-15 | 2021-01-21 | Intervet International B.V. | Caninized antibodies against canine ctla-4 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA314534A (en) * | 1931-08-25 | The United States Gypsum Company | Roof or floor | |
| WO2009126730A2 (en) * | 2008-04-09 | 2009-10-15 | The Trustees Of The University Of Pennsylvania | Canine single chain fragment variable antibody libraries and uses thereof |
| EP4326324A4 (en) * | 2021-04-21 | 2026-03-25 | Univ Pennsylvania | Canine Monoclonal Antibodies Against Canine Cytotoxic T Lymphocyte-Associated Protein 4 (CTLA-4) |
-
2022
- 2022-04-20 EP EP22792435.4A patent/EP4326324A4/en active Pending
- 2022-04-20 CA CA3216131A patent/CA3216131A1/en active Pending
- 2022-04-20 WO PCT/US2022/025614 patent/WO2022226102A1/en not_active Ceased
- 2022-04-20 JP JP2023565183A patent/JP7868811B2/ja active Active
-
2023
- 2023-10-20 US US18/491,182 patent/US12110331B2/en active Active
-
2024
- 2024-09-04 US US18/823,863 patent/US20250171541A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040181039A1 (en) | 2001-12-21 | 2004-09-16 | Krah Eugene Regis | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| WO2021009187A1 (en) | 2019-07-15 | 2021-01-21 | Intervet International B.V. | Caninized antibodies against canine ctla-4 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250171541A1 (en) | 2025-05-29 |
| JP2024516621A (ja) | 2024-04-16 |
| EP4326324A4 (en) | 2026-03-25 |
| CA3216131A1 (en) | 2022-10-27 |
| US20240109967A1 (en) | 2024-04-04 |
| EP4326324A1 (en) | 2024-02-28 |
| WO2022226102A1 (en) | 2022-10-27 |
| US12110331B2 (en) | 2024-10-08 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250331 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250331 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260106 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20260312 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20260313 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20260312 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260406 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260415 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260512 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7868811 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |